Argenx stock heads into the open after a muted analyst-driven move

At the close on September 8, 2026, Argenx stock on Euronext Brussels was quoted around EUR 868.40 after a marginal 0.12% dip, while recent analyst actions highlighted support for the shares. Today, investors watch Argenx stock ahead of the open following fresh conference commentary and rating updates.

Argenx stock closed around EUR 868.40 on Euronext Brussels on September 8, 2026, edging down 0.12% on the day per exchange data cited in recent coverage. The move left the shares near their 52-week high, with year-to-date performance of roughly 21.12% against about 14.44% for the BEL 20 home index over the same period.

September 8, 2026 in numbers

Argenx SE (ISIN NL0010832176, Euronext Brussels: ARGX) ended the September 8, 2026 session at about EUR 868.40 on its home market, a 0.12% decline from the prior close, with the price sitting close to the upper end of its 52-week range according to BEL 20 comparison data. The same metrics showed Argenx up roughly 20.65% year-to-date versus about 14.44% for the BEL 20, underscoring that the slight daily loss followed a stronger multi-month run.

Analyst commentary formed part of the backdrop. As Zonebourse reported on September 8, 2026, Barclays maintained a positive rating on Argenx and lifted its euro-denominated price target from EUR 1,000 to EUR 1,100 after recent revenue momentum from the autoimmune drug Vyvgart. In parallel, US-listed shares drew renewed attention from US analysts; for example, GuruFocus noted that Wedbush reiterated an Outperform rating for Argenx on September 8, 2026 with a USD 1,150 price target, framing the Nasdaq listing as undervalued versus its own fair value estimate.

Today’s catalysts for Argenx

Beyond price targets, Argenx management remained visible ahead of today’s session. At the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, company leaders outlined a broader growth plan around Vyvgart and pipeline assets during a fireside chat, emphasizing the ambition to evolve from a single-product success into a wider immunology portfolio, as summarized by Investing.com. Looking slightly further ahead, an earnings overview compiled by Zonebourse points to October 22, 2026 as the next scheduled earnings date, meaning that today’s trade unfolds with investors digesting conference remarks and analyst support while the next formal quarterly update remains several weeks away.